<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429024</url>
  </required_header>
  <id_info>
    <org_study_id>3132245</org_study_id>
    <nct_id>NCT02429024</nct_id>
  </id_info>
  <brief_title>Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences</brief_title>
  <official_title>Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bio-Kinetic Europe, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LifeScan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences with patients&#xD;
      with Type I and Type II diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to demonstrate improved A1c in study subjects with type 1 and type 2&#xD;
      diabetes using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a&#xD;
      period of 24 weeks, compared to subjects using the OneTouch Verio® Flex BGM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A1c ≤ 7.0%</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in A1c from baseline</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity and percentage of glucose results within personalized glycemic ranges set by HCP at baseline.</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that performed SMBG tests as instructed by HCP.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in patient satisfaction ( DTSQ survey)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of SMS messages sent by the HCP</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare efficiency survey by the HCP</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneTouch Reveal® Mobile APP</intervention_name>
    <description>Diabetes management application for use on a mobile phone.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneTouch Verio® Flex BGMS</intervention_name>
    <description>Blood Glucose Monitoring System (BGMS)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, at least 18 years old (or the legal age of consent in the jurisdiction&#xD;
             in which the study is taking place) to 70 years old, inclusive;&#xD;
&#xD;
          -  Has an A1c ≥7.5 and ≤ 11.0% at screening visit;&#xD;
&#xD;
          -  It is medically appropriate in the opinion of the investigator for the Subject to&#xD;
             attempt to achieve a level of glycemic control in line with the ADA guidelines on&#xD;
             glyceamic recommendations (&lt;7.0% A1c, pre-prandial capillary glucose of 3.9-7.2mmol/l&#xD;
             and peak post-prandial glucose of &lt;10.0mmol/l);&#xD;
&#xD;
          -  Diagnosed with T2DM or T1DM for ≥ 3 month prior to screening;&#xD;
&#xD;
          -  Currently performing SMBG at home for diabetes management decisions and willing to&#xD;
             test SMBG ≥ 1 per day if subject has Type 2 diabetes and is on AHA and/or non-insulin&#xD;
             injectable (e.g. GLP-1) only, ≥ 2 per day if on basal insulin or premixed insulin; and&#xD;
             test ≥ 3 times per day if subject has Type 2 diabetes and is on MDI or subject has&#xD;
             Type 1 diabetes.&#xD;
&#xD;
          -  Willing to send and receive SMS messages using a sponsor smartphone at 2 weekly&#xD;
             intervals throughout the study (note: this inclusion applies to all subjects&#xD;
             regardless of whether they are subsequently randomized to control or intervention)&#xD;
&#xD;
          -  Is located in an area that can send and receive SMS messages and has access to a phone&#xD;
             signal to use the 3G network as required&#xD;
&#xD;
          -  On a stable dose of anti-hyperglycemic agents (AHA), including oral hypoglycemics&#xD;
             (OAs), non-insulin injectables (e.g. GLP-1) or insulin therapy ≥ 2 months prior to&#xD;
             screening; (Note: the definition of stable includes subjects who routinely self-adjust&#xD;
             insulin based on 'in the moment' SMBG values. Stable does not include actual diabetes&#xD;
             therapy changes (e.g. new oral medications, initiating insulin or changing insulin&#xD;
             regimen, insulin to carb ratio changes or basal to bolus insulin progression)&#xD;
&#xD;
          -  Anti-hyperglycemic agents (AHA)(OAs or GLP-1s) must be consistent with UK labeling for&#xD;
             the subject's insulin type;&#xD;
&#xD;
          -  Willingness to not use a CGM device during the study period;&#xD;
&#xD;
          -  Willingness to notify the study staff if they become pregnant during the study;&#xD;
&#xD;
          -  Willingness to practice an appropriate form of birth control during the study if of&#xD;
             child bearing potential;&#xD;
&#xD;
          -  Able to communicate (speak, read and write) in English, and able to understand and&#xD;
             sign the required study documents;&#xD;
&#xD;
          -  Have signed an informed consent (or regional equivalent) document indicating they&#xD;
             understand the purpose and procedures of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is unlikely to be compliant with the currently prescribed diabetes regimen, in the&#xD;
             opinion of the study staff;&#xD;
&#xD;
          -  Currently pregnant or planning pregnancy within the duration of the study or breast&#xD;
             feeding;&#xD;
&#xD;
          -  Has unstable (rapidly progressing) retinopathy that in the opinion of the study staff&#xD;
             may require surgical treatment (including laser photocoagulation) during the study&#xD;
&#xD;
          -  Is currently on or received treatment during the past 3 months with Systemic&#xD;
             corticosteroids or anti-psychotic drugs or prescription cannabinoid&#xD;
&#xD;
          -  Is currently psychiatrically unstable in the opinion of the study staff&#xD;
&#xD;
          -  Has known clinically significant and/or unstable medical conditions, in the opinion of&#xD;
             the study staff, including: Cardiovascular disease, Hematological disease, Hepatic&#xD;
             disease, Gastrointestinal disease, Endocrine/metabolic disorders and Neurologic&#xD;
             disease&#xD;
&#xD;
          -  Malignant neoplasm requiring treatment in the past 5 years, other than basal&#xD;
             cell/squamous cell carcinoma of the skin&#xD;
&#xD;
          -  History of major surgery within 6 months&#xD;
&#xD;
          -  Has had any condition that in the opinion of the study staff that would complicate or&#xD;
             compromise the study, or the well being of the Subject&#xD;
&#xD;
          -  Subject is an employee of the investigator or clinical site;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Grady</last_name>
    <role>Study Director</role>
    <affiliation>LifeScan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioKinetic Europe Ltd</name>
      <address>
        <city>Belfast</city>
        <state>Antrim</state>
        <zip>BT2 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Centre, Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Diabetes Institute</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>A1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

